Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA

Journal Article · · Life Science Alliance
 [1];  [1];  [1];  [2];  [1];  [1];  [1];  [1];  [1];  [2];  [2];  [2];  [2];  [3];  [3];  [3];  [3];  [3];  [4];  [4] more »;  [5];  [3];  [2];  [1] « less
  1. Anacor Pharmaceuticals, Palo Alto, CA (United States)
  2. Infectious Disease Research Inst., Seattle, WA (United States)
  3. Colorado State Univ., Fort Collins, CO (United States)
  4. Texas A & M Univ., College Station, TX (United States)
  5. Stony Brook Univ., NY (United States)
+ Show Author Affiliations
New antitubercular agents are needed to combat the spread of multidrug- and extensively drug-resistant strains of Mycobacterium tuberculosis. The frontline antitubercular drug isoniazid (INH) targets the mycobacterial enoyl-ACP reductase, InhA. Resistance to INH is predominantly through mutations affecting the prodrug-activating enzyme KatG. Here, we report the identification of the diazaborines as a new class of direct InhA inhibitors. The lead compound, AN12855, exhibited in vitro bactericidal activity against replicating bacteria and was active against several drug-resistant clinical isolates. Biophysical and structural investigations revealed that AN12855 binds to and inhibits the substrate-binding site of InhA in a cofactor-independent manner. AN12855 showed good drug exposure after i.v. and oral delivery, with 53% oral bioavailability. Delivered orally, AN12855 exhibited dose-dependent efficacy in both an acute and chronic murine model of tuberculosis infection that was comparable with INH. Combined, AN12855 is a promising candidate for the development of new antitubercular agents.
Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
Bill & Melinda Gates Foundation; National Institutes of Health (NIH)
OSTI ID:
1545852
Journal Information:
Life Science Alliance, Journal Name: Life Science Alliance Journal Issue: 3 Vol. 1; ISSN 2575-1077
Publisher:
Cold Spring Harbor Laboratory PressCopyright Statement
Country of Publication:
United States
Language:
ENGLISH

References (37)

Towards a new tuberculosis drug: pyridomycin – nature's isoniazid journal September 2012
Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor journal June 2016
Crystallographic studies on the binding of isonicotinyl-NAD adduct to wild-type and isoniazid resistant 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis journal September 2007
Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model journal July 2008
Enzymic Characterization of the Target for Isoniazid in Mycobacterium tuberculosis journal July 1995
Inhibition of InhA, the Enoyl Reductase from Mycobacterium tuberculosis , by Triclosan and Isoniazid † journal July 2000
Roles of Tyrosine 158 and Lysine 165 in the Catalytic Mechanism of InhA, the Enoyl-ACP Reductase from Mycobacterium tuberculosis † journal October 1999
Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors journal February 2017
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis journal August 1992
Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid journal August 2006
The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance journal November 2003
A Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosis journal March 2010
A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging journal May 2012
A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase journal December 1996
Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosis journal January 1998
Direct inhibitors of InhA are active against Mycobacterium tuberculosis journal January 2015
Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria journal January 2013
Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates journal January 2004
Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models journal May 2005
Rapid Microbiologic and Pharmacologic Evaluation of Experimental Compounds against Mycobacterium tuberculosis journal March 2006
Protein Binding of Antimicrobials: Methods for Quantification and for Investigation of its Impact on Bacterial Killing journal January 2009
Optimisation of Bioluminescent Reporters for Use with Mycobacteria journal May 2010
A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis journal April 2013
Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis journal September 2013
Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review journal March 2015
Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds journal March 2012
Measuring Minimum Inhibitory Concentrations in Mycobacteria book January 2009
Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis journal September 2016
Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA journal December 2017
Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA journal December 2013
Crystal Structure of the Mycobacterium tuberculosis Enoyl-ACP Reductase, InhA, in Complex with NAD + and a C16 Fatty Acyl Substrate journal May 1999
A Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosis journal March 2010
Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria journal January 2013
Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates journal January 2004
Preclinical Testing of the Nitroimidazopyran PA-824 for Activity against Mycobacterium tuberculosis in a Series of In Vitro and In Vivo Models journal May 2005
Rapid Microbiologic and Pharmacologic Evaluation of Experimental Compounds against Mycobacterium tuberculosis journal March 2006
Positive Outcomes Influence the Rate and Time to Publication, but Not the Impact Factor of Publications of Clinical Trial Results journal January 2013

Cited By (1)

Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model journal April 2019

Similar Records

High Affinity Inha Inhibitors with Activity Against Drug-Resistant Strains of Mycobacterium Tuberculosis
Journal Article · Sat Dec 31 23:00:00 EST 2005 · ACS Chem. Biol. · OSTI ID:914315
Triclosan Derivatives: Towards Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis
Journal Article · Tue Jun 30 00:00:00 EDT 2009 · ChemMedChem · OSTI ID:1005696
Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis
Journal Article · Wed Aug 24 00:00:00 EDT 2011 · Mol. Microbiol. · OSTI ID:1023043

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
Medical Research
Microbiology
Virology & Host Pathogen Interaction